Loading…
Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study
Summary Objective To investigate the risk of hypothyroidism after radioiodine (131I) treatment for hyperfunctioning thyroid nodules. Design Retrospective analysis of patients treated with 131I for hyperfunctioning thyroid nodules and followed up for a maximum of 20 years. Patients A total of 346...
Saved in:
| Published in: | Clinical endocrinology (Oxford) 2005-03, Vol.62 (3), p.331-335 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3928-622c4ed088960768bc4cf39c06bbadb10ad4084233acafcae969b0e82bac358f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3928-622c4ed088960768bc4cf39c06bbadb10ad4084233acafcae969b0e82bac358f3 |
| container_end_page | 335 |
| container_issue | 3 |
| container_start_page | 331 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 62 |
| creator | Ceccarelli, Claudia Bencivelli, Walter Vitti, Paolo Grasso, Lucia Pinchera, Aldo |
| description | Summary
Objective To investigate the risk of hypothyroidism after radioiodine (131I) treatment for hyperfunctioning thyroid nodules.
Design Retrospective analysis of patients treated with 131I for hyperfunctioning thyroid nodules and followed up for a maximum of 20 years.
Patients A total of 346 patients treated with 131I in the years 1975–95, for a single hyperfunctioning nodule.
Measurements Hypothyroidism was defined as TSH levels > 3·7 mU/l. Kaplan–Meier survival analysis was used to analyse permanence of euthyroidism after 131I. A stepwise Cox proportional hazard model was used to identify factors influencing the progression to hypothyroidism.
Results The cumulative incidence of hypothyroidism was 7·6% at 1 year, 28% at 5 years, 46% at 10 years and 60% at 20 years. Age (P |
| doi_str_mv | 10.1111/j.1365-2265.2005.02218.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_198833388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>811331661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3928-622c4ed088960768bc4cf39c06bbadb10ad4084233acafcae969b0e82bac358f3</originalsourceid><addsrcrecordid>eNqNkN2K1DAUx4Mo7uzoK0gQxKvWk6RNU8ELGfZDWGcR_LgMaZI6GWeabtLq9G18Fp_M1Bl2b81FEji__zmHH0KYQE7SebPNCeNlRikvcwpQ5kApEfnhEVrcFx6jBTCADDgvztB5jFtIpIDqKTojZcWgIOUCbW7HQfu9xb7FQRnnnTeusxlhBA8bG1Q_YdfhzdTb0I6dHpzvXPc91abgncGdN-POxrdYYQp_fk9WhfgaBzsEH3ub8J8Wx2E00zP0pFW7aJ-f3iX6cnnxeXWd3dxefVi9v8k0q6nIOKW6sAaEqDlUXDS60C2rNfCmUaYhoEwBoqCMKa1arWzN6wasoI3SrBQtW6KXx7598HejjYPc-jF0aaQktRCMsXQtkThCOq0Zg21lH9xehUkSkLNhuZWzSDmLlLNh-c-wPKToi1P_sdlb8xA8KU3AqxOgola7NqhOu_jA8bICInji3h25X25np_9eQK4u1vMv5bNj3sXBHu7zKvyQvGJVKb-tr2T96Xr9lX9ksmJ_AS-1py0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198833388</pqid></control><display><type>article</type><title>Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Ceccarelli, Claudia ; Bencivelli, Walter ; Vitti, Paolo ; Grasso, Lucia ; Pinchera, Aldo</creator><creatorcontrib>Ceccarelli, Claudia ; Bencivelli, Walter ; Vitti, Paolo ; Grasso, Lucia ; Pinchera, Aldo</creatorcontrib><description>Summary
Objective To investigate the risk of hypothyroidism after radioiodine (131I) treatment for hyperfunctioning thyroid nodules.
Design Retrospective analysis of patients treated with 131I for hyperfunctioning thyroid nodules and followed up for a maximum of 20 years.
Patients A total of 346 patients treated with 131I in the years 1975–95, for a single hyperfunctioning nodule.
Measurements Hypothyroidism was defined as TSH levels > 3·7 mU/l. Kaplan–Meier survival analysis was used to analyse permanence of euthyroidism after 131I. A stepwise Cox proportional hazard model was used to identify factors influencing the progression to hypothyroidism.
Results The cumulative incidence of hypothyroidism was 7·6% at 1 year, 28% at 5 years, 46% at 10 years and 60% at 20 years. Age (P < 0·01), 24‐th 131I uptake (P < 0·05) and previous treatment with methimazole (MMI, P < 0·1) were associated with a faster progression towards hypothyroidism, while thyroid and nodule size, thyroid status at diagnosis and degree of extranodular thyroid parenchymal suppression had no influence. In hyperthyroid patients with partial parenchymal suppression, however, previous MMI treatment was the most important prognostic factor (P < 0·01).
Conclusions After 20 years of follow‐up, 60% of patients treated with 131I for a single hyperfunctioning nodule are hypothyroid. Factors increasing the risk of hypothyroidism are age, 131I uptake and MMI pretreatment. The prognostic value of this last factor, however, depends on the degree of suppression of the extranodular thyroid parenchyma at the scan.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/j.1365-2265.2005.02218.x</identifier><identifier>PMID: 15730415</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; Age Factors ; Aged ; Antithyroid Agents - adverse effects ; Biological and medical sciences ; Disease Progression ; Endocrinopathies ; Epidemiologic Methods ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Hyperthyroidism - radiotherapy ; Hypothyroidism - etiology ; Iodine Radioisotopes - adverse effects ; Iodine Radioisotopes - therapeutic use ; Male ; Medical sciences ; Methimazole - adverse effects ; Middle Aged ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Radiation Injuries - etiology ; Thyroid Gland - physiology ; Thyroid Nodule - radiotherapy ; Thyroid. Thyroid axis (diseases) ; Thyrotropin - blood ; Treatment Outcome ; Vertebrates: endocrinology</subject><ispartof>Clinical endocrinology (Oxford), 2005-03, Vol.62 (3), p.331-335</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Blackwell Publishing Mar 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3928-622c4ed088960768bc4cf39c06bbadb10ad4084233acafcae969b0e82bac358f3</citedby><cites>FETCH-LOGICAL-c3928-622c4ed088960768bc4cf39c06bbadb10ad4084233acafcae969b0e82bac358f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16570186$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15730415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ceccarelli, Claudia</creatorcontrib><creatorcontrib>Bencivelli, Walter</creatorcontrib><creatorcontrib>Vitti, Paolo</creatorcontrib><creatorcontrib>Grasso, Lucia</creatorcontrib><creatorcontrib>Pinchera, Aldo</creatorcontrib><title>Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Summary
Objective To investigate the risk of hypothyroidism after radioiodine (131I) treatment for hyperfunctioning thyroid nodules.
Design Retrospective analysis of patients treated with 131I for hyperfunctioning thyroid nodules and followed up for a maximum of 20 years.
Patients A total of 346 patients treated with 131I in the years 1975–95, for a single hyperfunctioning nodule.
Measurements Hypothyroidism was defined as TSH levels > 3·7 mU/l. Kaplan–Meier survival analysis was used to analyse permanence of euthyroidism after 131I. A stepwise Cox proportional hazard model was used to identify factors influencing the progression to hypothyroidism.
Results The cumulative incidence of hypothyroidism was 7·6% at 1 year, 28% at 5 years, 46% at 10 years and 60% at 20 years. Age (P < 0·01), 24‐th 131I uptake (P < 0·05) and previous treatment with methimazole (MMI, P < 0·1) were associated with a faster progression towards hypothyroidism, while thyroid and nodule size, thyroid status at diagnosis and degree of extranodular thyroid parenchymal suppression had no influence. In hyperthyroid patients with partial parenchymal suppression, however, previous MMI treatment was the most important prognostic factor (P < 0·01).
Conclusions After 20 years of follow‐up, 60% of patients treated with 131I for a single hyperfunctioning nodule are hypothyroid. Factors increasing the risk of hypothyroidism are age, 131I uptake and MMI pretreatment. The prognostic value of this last factor, however, depends on the degree of suppression of the extranodular thyroid parenchyma at the scan.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Antithyroid Agents - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Endocrinopathies</subject><subject>Epidemiologic Methods</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Hyperthyroidism - radiotherapy</subject><subject>Hypothyroidism - etiology</subject><subject>Iodine Radioisotopes - adverse effects</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methimazole - adverse effects</subject><subject>Middle Aged</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Radiation Injuries - etiology</subject><subject>Thyroid Gland - physiology</subject><subject>Thyroid Nodule - radiotherapy</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Thyrotropin - blood</subject><subject>Treatment Outcome</subject><subject>Vertebrates: endocrinology</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqNkN2K1DAUx4Mo7uzoK0gQxKvWk6RNU8ELGfZDWGcR_LgMaZI6GWeabtLq9G18Fp_M1Bl2b81FEji__zmHH0KYQE7SebPNCeNlRikvcwpQ5kApEfnhEVrcFx6jBTCADDgvztB5jFtIpIDqKTojZcWgIOUCbW7HQfu9xb7FQRnnnTeusxlhBA8bG1Q_YdfhzdTb0I6dHpzvXPc91abgncGdN-POxrdYYQp_fk9WhfgaBzsEH3ub8J8Wx2E00zP0pFW7aJ-f3iX6cnnxeXWd3dxefVi9v8k0q6nIOKW6sAaEqDlUXDS60C2rNfCmUaYhoEwBoqCMKa1arWzN6wasoI3SrBQtW6KXx7598HejjYPc-jF0aaQktRCMsXQtkThCOq0Zg21lH9xehUkSkLNhuZWzSDmLlLNh-c-wPKToi1P_sdlb8xA8KU3AqxOgola7NqhOu_jA8bICInji3h25X25np_9eQK4u1vMv5bNj3sXBHu7zKvyQvGJVKb-tr2T96Xr9lX9ksmJ_AS-1py0</recordid><startdate>200503</startdate><enddate>200503</enddate><creator>Ceccarelli, Claudia</creator><creator>Bencivelli, Walter</creator><creator>Vitti, Paolo</creator><creator>Grasso, Lucia</creator><creator>Pinchera, Aldo</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>200503</creationdate><title>Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study</title><author>Ceccarelli, Claudia ; Bencivelli, Walter ; Vitti, Paolo ; Grasso, Lucia ; Pinchera, Aldo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3928-622c4ed088960768bc4cf39c06bbadb10ad4084233acafcae969b0e82bac358f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Antithyroid Agents - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Endocrinopathies</topic><topic>Epidemiologic Methods</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Hyperthyroidism - radiotherapy</topic><topic>Hypothyroidism - etiology</topic><topic>Iodine Radioisotopes - adverse effects</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methimazole - adverse effects</topic><topic>Middle Aged</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Radiation Injuries - etiology</topic><topic>Thyroid Gland - physiology</topic><topic>Thyroid Nodule - radiotherapy</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Thyrotropin - blood</topic><topic>Treatment Outcome</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ceccarelli, Claudia</creatorcontrib><creatorcontrib>Bencivelli, Walter</creatorcontrib><creatorcontrib>Vitti, Paolo</creatorcontrib><creatorcontrib>Grasso, Lucia</creatorcontrib><creatorcontrib>Pinchera, Aldo</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ceccarelli, Claudia</au><au>Bencivelli, Walter</au><au>Vitti, Paolo</au><au>Grasso, Lucia</au><au>Pinchera, Aldo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2005-03</date><risdate>2005</risdate><volume>62</volume><issue>3</issue><spage>331</spage><epage>335</epage><pages>331-335</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>Summary
Objective To investigate the risk of hypothyroidism after radioiodine (131I) treatment for hyperfunctioning thyroid nodules.
Design Retrospective analysis of patients treated with 131I for hyperfunctioning thyroid nodules and followed up for a maximum of 20 years.
Patients A total of 346 patients treated with 131I in the years 1975–95, for a single hyperfunctioning nodule.
Measurements Hypothyroidism was defined as TSH levels > 3·7 mU/l. Kaplan–Meier survival analysis was used to analyse permanence of euthyroidism after 131I. A stepwise Cox proportional hazard model was used to identify factors influencing the progression to hypothyroidism.
Results The cumulative incidence of hypothyroidism was 7·6% at 1 year, 28% at 5 years, 46% at 10 years and 60% at 20 years. Age (P < 0·01), 24‐th 131I uptake (P < 0·05) and previous treatment with methimazole (MMI, P < 0·1) were associated with a faster progression towards hypothyroidism, while thyroid and nodule size, thyroid status at diagnosis and degree of extranodular thyroid parenchymal suppression had no influence. In hyperthyroid patients with partial parenchymal suppression, however, previous MMI treatment was the most important prognostic factor (P < 0·01).
Conclusions After 20 years of follow‐up, 60% of patients treated with 131I for a single hyperfunctioning nodule are hypothyroid. Factors increasing the risk of hypothyroidism are age, 131I uptake and MMI pretreatment. The prognostic value of this last factor, however, depends on the degree of suppression of the extranodular thyroid parenchyma at the scan.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>15730415</pmid><doi>10.1111/j.1365-2265.2005.02218.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2005-03, Vol.62 (3), p.331-335 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_journals_198833388 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Age Factors Aged Antithyroid Agents - adverse effects Biological and medical sciences Disease Progression Endocrinopathies Epidemiologic Methods Female Fundamental and applied biological sciences. Psychology Humans Hyperthyroidism - radiotherapy Hypothyroidism - etiology Iodine Radioisotopes - adverse effects Iodine Radioisotopes - therapeutic use Male Medical sciences Methimazole - adverse effects Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Radiation Injuries - etiology Thyroid Gland - physiology Thyroid Nodule - radiotherapy Thyroid. Thyroid axis (diseases) Thyrotropin - blood Treatment Outcome Vertebrates: endocrinology |
| title | Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T08%3A50%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20radioiodine-131%20therapy%20in%20hyperfunctioning%20thyroid%20nodules:%20a%2020%C2%A0years'%20retrospective%20study&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Ceccarelli,%20Claudia&rft.date=2005-03&rft.volume=62&rft.issue=3&rft.spage=331&rft.epage=335&rft.pages=331-335&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1111/j.1365-2265.2005.02218.x&rft_dat=%3Cproquest_cross%3E811331661%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3928-622c4ed088960768bc4cf39c06bbadb10ad4084233acafcae969b0e82bac358f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=198833388&rft_id=info:pmid/15730415&rfr_iscdi=true |